{
    "clinical_study": {
        "@rank": "130936", 
        "arm_group": [
            {
                "arm_group_label": "Arm 1: isavuconazole only", 
                "arm_group_type": "Experimental", 
                "description": "Isavuconazole three times per day (TID) on Days 1-2, and once daily (QD) on Days 3 thru 13"
            }, 
            {
                "arm_group_label": "Arm 2 : LPV/RTV only", 
                "arm_group_type": "Experimental", 
                "description": "Lopinavir/ritonavir (LPV/RTV) twice daily (BID) on Days 1-12 and once on Day 13"
            }, 
            {
                "arm_group_label": "Arm 3: isavuconazole and LPV/RTV", 
                "arm_group_type": "Experimental", 
                "description": "Isavuconazole three times per day (TID) on Days 1-2, and once daily (QD) on Days 3 thru 13 in combination with lopinavir/ritonavir  twice daily (BID) on Days 1-13"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this two part study is to assess the effect of multiple doses of\n      isavuconazole on the pharmacokinetics of multiple doses of lopinavir/ritonavir and the\n      effect of multiple doses of lopinavir/ritonavir on the pharmacokinetics of isavuconazole.\n\n      Part 1 of the study includes 12 subjects randomized to receive either isavuconazole alone or\n      isavuconazole in combination with lopinavir/ritonavir.  The purpose of  Part 1 is to\n      evaluate safety and tolerability and to establish the effect of multiple doses of\n      lopinavir/ritonavir on isavuconazole.\n\n      Part 2, if initiated, includes 54 subjects randomized to receive isavuconazole alone,\n      lopinavir/ritonavir alone, or isavuconazole in combination with lopinavir/ritonavir."
        }, 
        "brief_title": "Drug-drug Interaction Study Between Lopinavir/Ritonavir and Isavuconazole", 
        "completion_date": {
            "#text": "October 2012", 
            "@type": "Actual"
        }, 
        "condition": [
            "Pharmacokinetics of Isavuconazole", 
            "Pharmacokinetics of Lopinavir/Ritonavir", 
            "Healthy Volunteers"
        ], 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  The subject has a body weight of at least 45 kg and has a body mass index (BMI) of 18\n             to 32 kg/m2, inclusive\n\n          -  Results for aspartate aminotransferase (AST) and alanine aminotransferase (ALT),\n             total bilirubin, lipase, amylase, glucose and triglycerides must be within the normal\n             range\n\n          -  The female subject agrees to sexual abstinence, or is surgically sterile,\n             postmenopausal (defined as at least 2 years at Screening without menses), or using a\n             medically acceptable double barrier method (e.g. spermicide and diaphragm, or\n             spermicide and condom) to prevent pregnancy and agrees to continue using this method\n             from Screening until 3 weeks after the follow-up visit at the end of the study; and\n             is not lactating or pregnant as documented by negative pregnancy tests at Screening\n             and Day -1\n\n          -  The male subject agrees to sexual abstinence, is surgically sterile, or is using a\n             medically acceptable method to prevent pregnancy and agrees to continue using this\n             method from Screening until 3 weeks after the follow-up visit at the end of the study\n\n        Exclusion Criteria:\n\n          -  The subject has a history of unexplained syncope, cardiac arrest, unexplained cardiac\n             arrhythmia or torsade de pointes, structural heart disease, or family history of Long\n             QT syndrome (suggested by sudden death of a close relative at a young age due to\n             possible or probable cardiac causes)\n\n          -  The subject has a history of pancreatitis\n\n          -  The subject has a positive result for hepatitis C antibodies, hepatitis B surface\n             antigen at Screening or is known to be positive for human immunodeficiency virus\n             (HIV)\n\n          -  The subject has a known or suspected allergy to any of the components of the trial\n             products including lopinavir/ritonavir or the azole class of compounds, or a history\n             of multiple and/or severe allergies to drugs or foods (as judged by the\n             investigator), or a history of severe anaphylactic reactions-  - The subject is a\n             smoker (any use of tobacco or nicotine containing products) within 6 months prior to\n             Screening\n\n          -  The subject has had treatment with prescription drugs or complementary and\n             alternative medicines within 14 days prior to Day -1, or over-the-counter medications\n             within 1 week prior to Day -1, with the exception of acetaminophen up to 2 g/day\n\n          -  The subject has a recent history (within the last 2 years) of drug or alcohol abuse,\n             as defined by the investigator, or a positive drug and/or alcohol screen\n\n          -  The subject has participated in a previous isavuconazole study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "68", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 6, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01660477", 
            "org_study_id": "9766-CL-0035"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Arm 1: isavuconazole only", 
                    "Arm 3: isavuconazole and LPV/RTV"
                ], 
                "description": "oral", 
                "intervention_name": "Isavuconazole", 
                "intervention_type": "Drug", 
                "other_name": "BAL8557"
            }, 
            {
                "arm_group_label": [
                    "Arm 2 : LPV/RTV only", 
                    "Arm 3: isavuconazole and LPV/RTV"
                ], 
                "description": "oral", 
                "intervention_name": "Lopinavir/ritonavir", 
                "intervention_type": "Drug", 
                "other_name": "KALETRA\u00ae"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Ritonavir", 
                "Lopinavir"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Isavuconazole", 
            "Lopinavir/ritonavir", 
            "Healthy Volunteers", 
            "BAL8557", 
            "Kaletra \u00ae"
        ], 
        "lastchanged_date": "November 7, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Glendale", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "91206"
                }, 
                "name": "Parexel International"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase 1, Open-Label, Parallel Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of Multiple Doses of Lopinavir/Ritonavir and the Effects of Lopinavir/Ritonavir on the Pharmacokinetics of Multiple Doses of Isavuconazole in Healthy Adult Subjects", 
        "overall_official": {
            "affiliation": "Astellas Pharma Global Development", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "(Arms 1 and 3) Area under the concentration time curve during the during time interval between consecutive dosing (AUCtau) (tau=24)", 
                "measure": "Pharmacokinetic (PK) for isavuconazole:  AUCtau", 
                "safety_issue": "No", 
                "time_frame": "Part 1, Day 13:  predose, 0.5, 1, 2, 3, 4, 6, 8,10,12,16, and 24 hours post-dose"
            }, 
            {
                "description": "(Arms 2 and 3)  Maximum concentration (Cmax)", 
                "measure": "Pharmacokinetic (PK) profile for isavuconazole:  AUC tau and Cmax", 
                "safety_issue": "No", 
                "time_frame": "Part 2, Day 13: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16,  24 hours post dose"
            }, 
            {
                "description": "(Arms 2 and 3)  AUC during time interval between consecutive dosing (AUCtau) (tau=12)", 
                "measure": "Pharmacokinetic (PK) profile for lopinavir/ritonavir: AUC tau and Cmax", 
                "safety_issue": "No", 
                "time_frame": "Part 2, Day 13: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 hours post dose"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01660477"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "(Arms 1 and 3)", 
                "measure": "PK for isavuconazole (in plasma): trough concentration (Ctrough)", 
                "safety_issue": "No", 
                "time_frame": "Parts 1 and 2, Days 3, 5, 7, 9 and 11: pre-dose"
            }, 
            {
                "description": "(Arms 1 and 3) Time to attain Cmax (tmax)", 
                "measure": "PK profile for isavuconazole (in plasma): Cmax, tmax", 
                "safety_issue": "Yes", 
                "time_frame": "Parts 1 and 2, Day 13: predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12,16, and 24 hours post-dose"
            }, 
            {
                "description": "(Arms 2 and 3)", 
                "measure": "PK for lopinavir/ritonavir (in plasma): trough concentration (Ctrough)", 
                "safety_issue": "No", 
                "time_frame": "Part 2,  Days 3, 5, 7, 9 and 11: pre-dose"
            }, 
            {
                "description": "(Arms 2 and 3)", 
                "measure": "PK for lopinavir/ritonavir (in plasma): tmax", 
                "safety_issue": "No", 
                "time_frame": "Part 2, Day 13: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24 hours post dose"
            }, 
            {
                "measure": "Safety and tolerability of isavuconazole alone and in combination with lopinavir (LPV) and ritonavir (RTV) assessed by recording of adverse events, physical examination, clinical laboratory evaluation, electrocardiograms (ECGs) and vital signs", 
                "safety_issue": "No", 
                "time_frame": "Part 1, Days 1 - 20 \u00b1 2"
            }
        ], 
        "source": "Astellas Pharma Inc", 
        "sponsors": {
            "collaborator": {
                "agency": "Basilea Pharmaceutica International Ltd", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Astellas Pharma Global Development, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "November 2012"
    }
}